Tags

Type your tag names separated by a space and hit enter

Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients.
J Clin Endocrinol Metab. 1999 Aug; 84(8):2673-8.JC

Abstract

An interruption of continuous sc insulin infusion (CSII) of the insulin analog lispro should result in a more rapid metabolic deterioration of type 1 diabetic patients because of its pharmacokinetic characteristics. We analyzed the metabolic changes occurring during a 5-h interruption of CSII and the 5 h after restarting the pump in 10 type 1 diabetic patients. The study was a randomized, cross-over, open label design comparing insulin analog [Lispro (LP)] and regular insulin [Velosuline (VE)]. Plasma glucose, free insulin, glucagon, betahydroxybutyrate (beta-OHB), and nonesterified fatty acids (NEFA) were measured every hour from 0700 h (time zero) to 1700 h (600 min). After stopping CSII, the plasma glucose level was significantly higher in the LP group than in the VE group (P < 0.05-0.01). The plasma free insulin level decreased significantly with the two treatments, but was significantly lower with LP than with VE (P < 0.05-0.01). Plasma NEFA increased more rapidly and was significantly higher in the LP group than in the VE group (P < 0.01-0.05). Plasma beta-OHB increased earlier with LP, but was not statistically different between the treatments. After restarting the pump, plasma glucose decreased with LP, but continued to increase with VE, and the plasma free insulin peak occurred earlier and was greater with LP than with VE (P < 0.05). Plasma NEFA and beta-OHB levels decreased significantly with the two treatments, but more dramatically with LP treatment. Thus, a short interruption of Lispro in CSII is associated with an earlier, greater metabolic deterioration, but Lispro corrected this metabolic deterioration more effectively.

Authors+Show Affiliations

Centre d'Investigation Clinique-INSERM/Centre Hospitalier Universitaire de NANCY-Hôpital Jeanne d'Arc, Toul, France. cic@chu-nancy.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10443658

Citation

Guerci, B, et al. "Comparison of Metabolic Deterioration Between Insulin Analog and Regular Insulin After a 5-hour Interruption of a Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Patients." The Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 8, 1999, pp. 2673-8.
Guerci B, Meyer L, Sallé A, et al. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab. 1999;84(8):2673-8.
Guerci, B., Meyer, L., Sallé, A., Charrié, A., Dousset, B., Ziegler, O., & Drouin, P. (1999). Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. The Journal of Clinical Endocrinology and Metabolism, 84(8), 2673-8.
Guerci B, et al. Comparison of Metabolic Deterioration Between Insulin Analog and Regular Insulin After a 5-hour Interruption of a Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Patients. J Clin Endocrinol Metab. 1999;84(8):2673-8. PubMed PMID: 10443658.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. AU - Guerci,B, AU - Meyer,L, AU - Sallé,A, AU - Charrié,A, AU - Dousset,B, AU - Ziegler,O, AU - Drouin,P, PY - 1999/8/12/pubmed PY - 1999/8/12/medline PY - 1999/8/12/entrez SP - 2673 EP - 8 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 84 IS - 8 N2 - An interruption of continuous sc insulin infusion (CSII) of the insulin analog lispro should result in a more rapid metabolic deterioration of type 1 diabetic patients because of its pharmacokinetic characteristics. We analyzed the metabolic changes occurring during a 5-h interruption of CSII and the 5 h after restarting the pump in 10 type 1 diabetic patients. The study was a randomized, cross-over, open label design comparing insulin analog [Lispro (LP)] and regular insulin [Velosuline (VE)]. Plasma glucose, free insulin, glucagon, betahydroxybutyrate (beta-OHB), and nonesterified fatty acids (NEFA) were measured every hour from 0700 h (time zero) to 1700 h (600 min). After stopping CSII, the plasma glucose level was significantly higher in the LP group than in the VE group (P < 0.05-0.01). The plasma free insulin level decreased significantly with the two treatments, but was significantly lower with LP than with VE (P < 0.05-0.01). Plasma NEFA increased more rapidly and was significantly higher in the LP group than in the VE group (P < 0.01-0.05). Plasma beta-OHB increased earlier with LP, but was not statistically different between the treatments. After restarting the pump, plasma glucose decreased with LP, but continued to increase with VE, and the plasma free insulin peak occurred earlier and was greater with LP than with VE (P < 0.05). Plasma NEFA and beta-OHB levels decreased significantly with the two treatments, but more dramatically with LP treatment. Thus, a short interruption of Lispro in CSII is associated with an earlier, greater metabolic deterioration, but Lispro corrected this metabolic deterioration more effectively. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/10443658/Comparison_of_metabolic_deterioration_between_insulin_analog_and_regular_insulin_after_a_5_hour_interruption_of_a_continuous_subcutaneous_insulin_infusion_in_type_1_diabetic_patients_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem.84.8.5912 DB - PRIME DP - Unbound Medicine ER -